Science & Research | June 17th, 2022

New European registry on retinopathy of prematurity established – EU-ROP

Retinopathy of prematurity (ROP) is one of the leading causes for childhood blindness worldwide. Due to the limited number of treated patients per year and center, collecting and analyzing real-life data needs to be done in a collaborative multicenter approach. This is the idea behind the recently established EU-ROP registry (Clinicaltrials.gov identifier: NCT04939571).

The EU-ROP registry is an international, multicenter, observational registry study intended to run open-ended to collect and analyze data on infants treated for retinopathy of prematurity irrespective of the treatment modality. The registry is strictly observational; only clinical routine data is collected, no study-specific examinations or interventions are to be performed. Only data from treated ROP infants is collected, limiting the time commitment for data entry at participating centers. The EU-ROP data will help to better understand and improve ROP care and outcomes across Europe.

The EU-ROP project is currently financed by extramural grants from the University Medicine Greifswald, solicited through the EU-ROP principal investigator from Novartis AG and Bayer AG.

If you want to participate in the project or first want to get more information, please visit the project website: www.eu-rop.org or write an e-mail to contact@eu-rop.org.